cyclophilin
group
cellular
protein
peptidylprolyl
isomeras
enzymat
activ
catalyz
ci
tran
convers
prolinecontain
peptid
facilit
protein
fold
main
cyclophilin
human
be
cyclophilin
cyp
cypb
cypc
cypd
cype
cyp
natur
killer
nk
local
differ
cellular
compart
exampl
cypa
present
cytosol
cypb
cypc
resid
lumen
endoplasm
reticulum
cypd
present
mitochondria
cype
local
nucleu
cyclophilin
involv
life
cycl
wide
rang
virus
includ
hepat
c
viru
hcv
human
immunodefici
viru
vaccinia
viru
coronavirus
polyomaviru
bk
act
host
cofactor
essenti
viru
replic
cypa
main
cyclophilin
involv
directli
life
cycl
hcv
inhibit
peptidylprolyl
isomeras
activ
cyclophilin
inhibitor
shown
interfer
multipl
site
hcv
life
cycl
hepatocyt
affect
replic
also
hcv
secret
infect
cell
role
cellular
cyclophilin
hepat
b
viru
hbv
life
cycl
howev
poorli
understood
present
studi
investig
whether
hepatocyt
cyclophilin
involv
hbv
replic
hepat
b
surfac
antigen
hbsag
product
secret
effect
nonimmunosuppress
cyclophilin
inhibitor
alon
combin
direct
antivir
agent
target
hbv
polymeras
four
human
hepatoma
cell
line
produc
full
hbv
virion
hbsag
subvir
particl
use
studi
cell
japan
health
scienc
research
resourc
bank
osaka
japan
stabl
knockdown
kd
cypa
use
short
hairpin
cell
line
transfect
hbv
dna
cell
stabli
transfect
hbv
dna
heparg
cell
invitrogen
carlsbad
ca
infect
hbv
cell
cultur
c
co
dulbecco
modifi
eagl
medium
dmem
life
technolog
paisley
uk
fetal
calf
serum
fc
life
technolog
describ
previous
cypa
kd
cell
cultur
fc
plu
nonessenti
amino
acid
mgml
select
marker
puromycin
life
technolog
heparg
cell
termin
differenti
purchas
invitrogen
carlsbad
ca
cell
cultur
accord
manufactur
instruct
heparg
cell
user
guid
invitrogen
collagen
icoat
plate
initi
cell
grown
william
medium
e
heparg
thaw
plate
gener
purpos
medium
supplement
glutamax
invitrogen
prepar
standard
process
day
cell
maintain
william
medium
e
heparg
mainten
medium
supplement
plu
glutamax
cypa
kd
cell
transfect
hbv
plasmid
kindli
provid
professor
han
contain
headtotail
hbvdna
dimer
briefli
cell
densiti
well
seed
onto
plate
cultur
hour
c
reach
confluenc
cell
transfect
mg
fugen
roch
burgess
hill
uk
accord
manufactur
instruct
transfect
effici
determin
use
bgal
stain
kit
life
technolog
heparg
cell
infect
hbv
deriv
cultur
supernat
cell
describ
hbvinfect
heparg
cell
seed
cell
respect
onto
plate
maintain
c
cell
line
subsequ
treat
describ
later
cell
transfect
cypa
b
c
small
interf
rna
sirna
sigenom
smart
pool
thermo
scientif
dharmacon
epsom
uk
optim
knockdown
effect
cyclophilin
express
preliminari
experi
rang
sirna
concentr
specif
cyclophilin
conduct
test
nmoll
hour
see
supplementari
materi
method
section
cyclophilin
messeng
rna
mrna
express
baselin
differ
time
point
sirna
transfect
assess
realtim
polymeras
chain
reaction
pcr
primer
specif
cypa
b
c
optim
experi
sirna
stock
solut
mmoll
dilut
ml
optimem
medium
life
technolog
final
concentr
nmoll
cypa
cypd
sirna
nmoll
cypc
lipofectamin
invitrogen
life
technolog
dilut
ml
optimem
medium
incub
minut
room
temperatur
combin
dilut
sirna
dilut
lipofectamin
incub
minut
room
temperatur
cell
cell
per
well
treat
sirnalipofectamin
complex
incub
hour
c
nontarget
scrambl
sirna
use
neg
control
dehydrogenas
sirna
siglo
thermo
scientif
dharmacon
green
use
posit
control
sirna
deliveri
transfect
respect
specif
sirna
silenc
crosscheck
use
realtim
pcr
primer
specif
cypa
cypc
cypd
mrna
cell
transfect
cypa
cypc
cypd
sirna
respect
confirm
sirna
select
decreas
target
cyclophilin
mrna
approxim
wherea
cyclophilin
cypa
cypc
cypd
mrna
express
compar
control
scrambl
sirna
knockdown
effect
cypa
protein
test
western
blot
enzymelink
immunosorb
assay
elisa
describ
later
alisporivir
nonimmunosuppress
cyclophilin
inhibitor
telbivudin
nucleosid
analog
potent
inhibitor
hbvdna
polymeras
compound
provid
novarti
basel
switzerland
seri
experi
cell
use
stabli
transfect
transient
transfect
cypa
kd
cell
hbvinfect
heparg
cell
cultur
alon
sever
concentr
alisporivir
alisporivir
stock
solut
prepar
stock
dimethyl
sulfoxid
dmso
final
work
concentr
alisporivir
mgml
prepar
daili
fc
final
dmso
concentr
control
also
contain
dmso
cultur
media
replac
everi
hour
ml
fresh
alisporivircontain
nimcontain
medium
supernat
cell
collect
baselin
bl
hour
hbvinfect
heparg
cell
treat
alisporivir
day
cell
supernat
collect
bl
hour
supplementari
figur
condit
time
point
cell
test
least
independ
experi
condit
run
triplic
well
heparg
cypa
kd
cell
test
duplic
cultur
medium
replac
everi
hour
graphic
represent
result
viral
particl
secret
supernat
shown
time
point
start
zero
medium
chang
cytotox
assess
microscop
observ
cell
trypan
blue
exclus
andor
lactat
dehydrogenas
ldh
releas
supernat
use
ldhcytotox
assay
kit
biovis
research
product
mountain
view
ca
treat
cell
combin
alisporivir
alv
telbivudin
first
test
antivir
activ
rang
telbivudin
concentr
current
model
stock
solut
telbivudin
dmso
use
prepar
work
concentr
daili
rang
mmoll
telbivudin
supplementari
figur
cell
cultur
medium
contain
work
concentr
replac
daili
sampl
collect
bl
hour
base
experi
subsequ
combin
experi
telbivudin
use
mmoll
mgml
correspond
maximum
concentr
level
observ
clinic
studi
see
supplementari
materi
method
section
test
antivir
activ
alv
combin
telbivudin
cell
treat
hour
follow
alv
mgmltelbivudin
mmoll
alv
mgmltelbivudin
mmoll
alv
mgmltelbivudin
mmoll
alv
mgmltelbivudin
mmoll
intracellular
nucleocapsidassoci
viral
dna
extract
transfect
cell
hbvinfect
heparg
cell
describ
previous
cultur
supernat
treat
dnase
hour
c
minut
c
place
ice
minut
supernat
centrifug
rpm
pellet
discard
dna
extract
supernat
use
qiaamp
dna
mini
qiagen
kit
qiagen
sussex
uk
hbv
dna
quantit
taqman
realtim
polymeras
chain
reaction
appli
biosystem
appli
biosystem
paisley
uk
use
eurohep
hbv
standard
hbvdna
plasmid
southern
blot
analysi
mg
hind
iiitreat
intracellular
dna
analyz
agaros
gel
transfer
hybondxl
ge
healthcar
life
scienc
pittsburgh
pa
membran
describ
radioact
hbvspecif
probe
gener
sac
ihind
iii
fragment
deriv
nick
translat
purifi
spin
column
chromatographi
prehybrid
hybrid
wash
describ
previous
quantit
hbsag
cypa
cypb
elisa
hbsag
secret
cell
cultur
shbsag
intracellular
hbsag
ihbsag
quantit
use
commerci
avail
hbsag
elisa
abazym
needham
hbsag
level
quantit
triplic
cultur
supernat
cytoplasm
extract
stabli
transient
transfect
cell
standard
curv
establish
use
serial
dilut
known
quantiti
purifi
hbsag
protein
american
research
product
belmont
intracellular
cypa
cypb
level
supernat
quantit
elisa
describ
previous
statist
analys
perform
use
spss
packag
ibm
new
york
ny
oneway
analysi
varianc
use
follow
dunnett
post
hoc
test
compar
one
treatment
group
nontreat
group
tukey
post
hoc
test
use
multipl
comparison
group
p
valu
less
consid
statist
signific
alisporivir
treatment
cell
result
progress
reduct
secret
intracellular
nucleocapsidassoci
hbv
dna
depend
drug
concentr
time
drug
exposur
figur
b
secret
viral
dna
reduc
hour
treatment
alisporivir
mgml
compar
cell
incub
medium
p
level
intracellular
hbv
dna
also
reduc
approxim
hour
treatment
mgml
alisporivir
p
treatment
heparg
cell
also
reduc
secret
intracellular
nucleocapsidassoci
hbv
dna
howev
antivir
effect
lower
alisporivir
supplementari
figur
differ
alisporivir
reduc
hbvdna
level
particularli
appar
cell
mgml
vs
hbvdna
reduct
hour
cell
cultur
control
experi
transfect
effici
bgal
stain
show
hbv
replic
cell
alisporivir
treatment
hbvtransfect
cell
also
result
dosedepend
reduct
secret
intracellular
hbv
dna
profound
reduct
observ
hour
treatment
alisporivir
mgml
respect
mgml
respect
figur
overal
alisporivir
antivir
activ
greater
transient
transfect
cell
comparison
stabli
transfect
cell
p
secret
hbv
dna
p
cytoplasm
hbv
dna
state
earlier
alisporivir
mgml
reduc
intracellular
hbvdna
level
cell
respect
hour
treatment
figur
differ
even
appar
earlier
time
point
hour
intracellular
hbvdna
reduct
cell
cell
respect
figur
importantli
southern
blot
analysi
intracellular
dna
support
quantit
realtim
pcr
result
outlin
earlier
alisporivir
reduc
intracellular
hbv
dna
dosedepend
manner
figur
hbvinfect
heparg
cell
treat
alisporivir
day
start
hour
hbv
inocul
supplementari
figur
also
model
cyclophilin
inhibitor
reduc
hbvdna
level
figur
supplementari
figur
hour
treatment
highest
concentr
alisporivir
intracellular
nucleocapsidassoci
hbv
dna
reduc
respect
similar
effect
reduct
respect
cell
minim
chang
shbsag
ihbsag
level
figur
b
magnitud
reduct
shbsag
alisporivir
lower
reduct
hbvdna
level
supplementari
figur
cell
signific
reduct
shbsag
ihbsag
observ
two
highest
alisporivir
concentr
figur
signific
chang
seen
hour
treatment
mgml
alisporivir
shbsag
reduc
ihbsag
reduc
experi
alisporivir
treatment
cytotox
hbvtransfect
cell
shown
ldh
releas
assay
supplementari
figur
determin
rel
involv
differ
cyclophilin
hbv
replic
express
cypa
b
c
silenc
select
respect
sirna
figur
effici
transfect
sirna
deliveri
assess
siglo
dehydrogenas
respect
supplementari
figur
e
express
cypa
c
mrna
cell
reduc
markedli
comparison
control
treat
nontarget
scrambl
sirna
durat
experi
supplementari
figur
cypa
gene
silenc
also
effici
reduc
intracellular
cypa
protein
test
elisa
supplementari
figur
western
blot
supplementari
figur
secret
intracellular
hbvdna
level
reduc
respect
cypasilenc
cell
figur
secret
hbsag
reduc
cell
figur
cypasilenc
cell
treat
alisporivir
compar
cypasilenc
cell
without
alisporivir
cypa
alisporivir
determin
whether
alisporivir
inhibit
cellular
cyclophilin
would
enhanc
antivir
effect
silenc
cypa
addit
alv
result
decreas
level
secret
intracellular
nucleocapsidassoci
hbv
dna
shbsag
figur
also
use
cell
stabl
cypa
kd
supplementari
figur
assess
impact
hbv
replic
hbsag
secret
hbv
dna
reduc
cell
comparison
normal
cell
figur
ad
alisporivir
margin
effect
intracellular
nucleocapsidassoci
hbv
dna
affect
even
cell
line
reduct
figur
secret
hbsag
also
reduc
alisporivir
inhibit
hbv
replic
significantli
wherea
intracellular
hbsag
accumul
cell
figur
interestingli
treatment
cypa
kd
cell
alisporivir
mgml
profoundli
decreas
intracellular
hbsag
level
cypcsilenc
cell
secret
intracellular
nucleocapsidassoci
hbv
dna
reduc
respect
compar
neg
control
figur
b
hbsag
level
reduc
figur
result
silenc
cypd
similar
silenc
cypca
secret
intracellular
nucleocapsidassoci
hbv
dna
shbsag
reduc
respect
figur
f
cypa
silenc
sirna
result
greater
reduct
secret
hbv
dna
shbsag
compar
sirna
silenc
cypc
cypd
state
earlier
hour
treatment
silenc
cypa
reduc
secret
hbv
dna
figur
compar
cypc
cypdsilenc
cell
figur
time
point
shbsag
reduc
figur
compar
cypc
cypd
silenc
cell
figur
f
respect
interestingli
ad
alisporivir
cypc
cypdsilenc
cell
reduc
viral
paramet
measur
figur
increas
effect
presenc
alisporivir
seen
level
secret
intracellular
dna
well
shbsag
still
increas
cyclophilinsilenc
cell
hour
intracellular
nucleocapsidassoci
dna
hour
shbsag
addit
effect
alisporivir
howev
disappear
level
secret
intracellular
nucleocapsidassoci
hbv
dna
becam
low
cyclophilinsilenc
cell
cypa
repres
key
target
cyclophilin
inhibitor
analyz
chang
intracellular
cypa
level
untreat
alisporivirtr
cell
cell
cypa
level
time
lower
cell
figur
b
affect
alisporivir
treatment
wherea
cell
alisporivir
treatment
result
dosedepend
decreas
intracellular
cypa
level
correspond
level
cypb
cultur
supernat
cell
increas
steadili
depend
time
alisporivir
concentr
figur
accord
previou
find
cypb
releas
alisporivirtr
cell
heparg
cell
cypa
cypb
level
similar
data
shown
significantli
greater
reduct
hbv
replic
observ
alisporivir
combin
direct
antivir
agent
telbivudin
compar
alisporivir
alon
appar
lower
concentr
alisporivir
mgml
figur
secret
viral
dna
intracellular
nucleocapsidassoci
hbv
dna
reduc
respect
cell
treat
mgml
alisporivir
plu
mmoll
telbivudin
vs
cell
treat
alisporivir
alon
hour
figur
b
compar
figur
b
furthermor
hour
reduct
secret
hbv
dna
appar
alisporivir
plu
telbivudin
compar
telbivudin
alon
figur
combin
alisporivir
plu
telbivudin
similar
effect
shbsag
ihbsag
level
compar
alisporivir
alon
figur
compar
figur
b
hbv
smallest
human
dna
viru
uniqu
genom
organ
replic
mechan
viral
replic
take
place
cytoplasm
infect
hepatocyt
subset
hbvrna
transcript
pregenom
rna
envelop
press
rna
hbx
mrna
encod
structur
nonstructur
viral
protein
characterist
hbv
infect
spheric
filament
subvir
particl
compos
exclus
viral
envelop
protein
hostderiv
lipid
produc
fold
excess
full
virion
secret
hepatocyt
use
differ
vitro
hbv
model
stabli
transfect
transient
transfect
hbvinfect
heparg
cell
present
studi
show
alisporivir
inhibit
hbv
replic
cellular
cyclophilin
major
role
hbv
life
cycl
hepatocyt
block
cyclophilin
enzymat
activ
small
molecul
alisporivir
select
silenc
individu
cyclophilin
sirna
markedli
reduc
hbvdna
replic
well
hbsag
product
secret
cell
cypa
one
abund
cytosol
protein
approxim
cell
protein
present
studi
show
major
util
cyclophilin
hbv
replic
hbv
envelop
protein
secret
hepatocyt
experi
use
cell
stabl
cypa
kd
find
alv
enhanc
hbv
dna
hbsag
reduct
cypc
cypdsilenc
cell
show
cypa
import
format
intracellular
nucleocapsidassoci
hbv
dna
viral
secret
well
hbsag
secret
cell
quantit
intracellular
cypa
show
greater
amount
cell
like
explan
much
greater
effect
alisporivir
hbsag
secret
compar
cell
importantli
cyclophilin
inhibitor
alisporivir
block
cellular
cyclophilin
cell
dosedepend
reduct
hbv
dna
data
thu
suggest
model
antivir
effect
primarili
result
alisporivir
target
cyclophilin
eg
cypd
andor
cypc
lead
observ
hbvdna
reduct
cell
result
present
studi
togeth
previous
publish
data
indic
mechan
alisporivir
impact
hbv
replic
hbsag
product
like
involv
interfer
multipl
site
hbv
life
cycl
first
find
cyclophilin
inhibit
reduc
intracellular
nucleocapsidassoci
hbv
dna
cytoplasm
suggest
antivir
effect
product
new
virion
reduct
recircul
hbv
nucleocapsid
cytoplasm
nucleu
key
mechan
replenish
viral
templat
found
mark
reduct
intracellular
hbv
dna
cell
stabl
cypa
kd
along
intracellular
hbsag
accumul
previou
studi
shown
intracellular
interact
cypa
hbsag
close
associ
secret
liver
cell
thu
cyclophilin
inhibitor
disrupt
cypahbsag
complex
reduc
envelop
protein
secret
second
hepat
b
x
antigen
hbxag
essenti
hbv
replic
associ
outer
membran
mitochondria
regul
cytosol
calcium
signal
drive
hbv
replic
shown
block
cytosol
calcium
signal
open
mitochondri
permeabl
transit
pore
result
inhibit
cypd
therefor
block
cypd
interfer
hbxag
regul
calcium
impact
hbv
replic
neg
third
cypa
import
cofactor
lipid
apolipoprotein
b
apob
traffick
shown
decreas
apob
secret
well
egress
hcv
particl
cell
cellular
lipid
part
hbv
envelop
protein
impact
cyclophilin
inhibit
apob
secret
like
interfer
intracellular
format
secret
lipoprotein
part
hbv
viral
subvir
particl
fourth
recent
find
shown
sodium
taurochol
cotransport
polypeptid
membran
bile
acid
transport
express
liver
function
receptor
hbv
hepat
delta
viru
via
bind
moreov
cyclosporin
nonimmunosuppress
analogu
alisporivir
recent
shown
inhibit
hbv
entri
cell
block
sodium
taurochol
cotransport
polypeptid
cyclophilinindepend
mechan
ultim
treatment
goal
patient
chronic
hepat
b
prevent
develop
cirrhosi
liver
failur
hepatocellular
carcinoma
hbsag
hallmark
hbv
infect
hbsag
loss
without
seroconvers
antibodi
hepat
b
surfac
antigen
ideal
treatment
end
point
associ
improv
longterm
outcom
show
markedli
enhanc
antivir
tcell
reactiv
allow
therapi
stop
minim
risk
relaps
although
nucleo
ide
polymeras
antivir
potent
inhibitor
hbv
replic
result
profound
reduct
circul
hbv
littl
effect
hbsag
transcriptionsubvir
particl
product
hbsag
loss
report
occur
hbeagposit
patient
hbeagneg
patient
year
continu
treatment
clinic
implic
present
studi
provid
vitro
evid
support
new
therapeut
approach
chronic
hepat
b
combin
direct
antivir
agent
hbvdna
polymeras
inhibitor
hosttarget
antivir
alisporivir
like
increas
rate
hbsag
clearanc
alisporivir
hosttarget
antivir
agent
current
develop
treatment
chronic
hepat
c
analys
clinic
databas
involv
patient
show
alisporivir
well
toler
markedli
better
safeti
profil
given
interferonfre
treatment
interferoncontain
treatment
combin
treatment
hbv
nucleo
ide
polymeras
inhibitor
plu
alisporivir
could
benefici
interfer
multipl
site
hbv
life
cycl
especi
addit
effect
reduc
hbsag
product
secret
plu
block
hbv
entri
noninfect
hepatocyt
present
studi
combin
alisporivir
plu
telbivudin
show
greater
impact
hbsag
support
potenti
util
combin
deserv
test
clinic
studi
conclus
cyclophilin
involv
multipl
step
hbv
life
cycl
infect
hepatocyt
block
enzymat
activ
use
nonimmunosuppress
cyclophilin
inhibitor
reduc
viral
replic
hbv
envelop
protein
product
secret
combin
alisporivir
hosttarget
agent
hbv
polymeras
inhibitor
found
decreas
hbsag
product
markedli
well
hbv
replic
indic
potenti
util
effect
therapi
chronic
hepat
b
note
access
supplementari
materi
accompani
articl
visit
onlin
version
gastroenterolog
wwwgastrojournalorg
http
